Isis Pharmaceuticals Inc Sample Contracts

ISIS PHARMACEUTICALS INC ANTISENSE THERAPEUTICS LTD STOCK PURCHASE AGREEMENT
Stock Purchase Agreement • January 4th, 2002 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Victoria
AutoNDA by SimpleDocs
ARTICLE II REPRESENTATIONS AND WARRANTIES OF THE COMPANY
Securities Purchase Agreement • August 29th, 2001 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
EXHIBIT B
Supply Agreement • August 29th, 2001 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
Common Stock
Underwriting Agreement • October 22nd, 2001 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
IONIS PHARMACEUTICALS, INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of June 12, 2023 1.75% Convertible Senior Notes due 2028
Indenture • June 12th, 2023 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations • New York

INDENTURE dated as of June 12, 2023 between IONIS PHARMACEUTICALS, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee,” as more fully set forth in Section 1.01).

LOAN AGREEMENT
Loan Agreement • August 29th, 2001 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
ARTICLE I
Purchase Agreement • August 14th, 1998 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
BY AND BETWEEN ORASENSE LTD
License Agreement • June 16th, 1999 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
BETWEEN
License Agreement • January 28th, 2000 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
To: Ionis Pharmaceuticals, Inc. Carlsbad, CA 92010 Attention: General Counsel Email: legalnotices@ionisph.com
Ionis Pharmaceuticals Inc • April 13th, 2021 • Pharmaceutical preparations • New York

The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between [_______] (“Dealer”) and Ionis Pharmaceuticals, Inc. (“Counterparty”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. Each party further agrees that this Confirmation together with the Agreement evidence a complete binding agreement between Counterparty and Dealer as to the subject matter and terms of the Transaction to which this Confirmation relates, and shall supersede all prior or contemporaneous written or oral communications with respect thereto.

AND
Rights Agreement • December 13th, 2000 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) 200.83 and 240.24b-2 DEVELOPMENT AND LICENSE AGREEMENT
Development and License Agreement • October 11th, 2001 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New Jersey
2002 NON-EMPLOYEE DIRECTORS' STOCK OPTION PLAN GRANT NOTICE
Non-Statutory Stock Option Agreement • April 1st, 2002 • Isis Pharmaceuticals Inc • Pharmaceutical preparations
AutoNDA by SimpleDocs
LOAN AGREEMENT
Loan Agreement • July 21st, 2017 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations • New York

THIS LOAN AGREEMENT, dated as of July 18, 2017 (as amended, restated, replaced, supplemented or otherwise modified from time to time, this “Agreement”), between UBS AG, by and through its branch office at 1285 Avenue of the Americas, New York, New York, having an address at 1285 Avenue of the Americas, 11th Floor, New York, New York 10019 (together with its successors and assigns, collectively, “Lender”), and IONIS FARADAY, LLC, a Delaware limited liability company having an address at 2855 Gazelle Court, Carlsbad, California 92010 (together with its permitted successors and assigns, collectively, “Borrower”).

IONIS PHARMACEUTICALS, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of December 19, 2019 0.125% Convertible Senior Notes due 2024
Ionis Pharmaceuticals Inc • December 23rd, 2019 • Pharmaceutical preparations • New York

INDENTURE dated as of December 19, 2019 between Ionis Pharmaceuticals, Inc., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and U.S. Bank National Association, a national banking association, as trustee (the “Trustee,” as more fully set forth in Section 1.01).

AGREEMENT BETWEEN
Research and Development Agreement • June 14th, 1999 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
COMMON STOCK PURCHASE AGREEMENT Dated May 30, 2006 by and between ISIS PHARMACEUTICALS, INC. and AZIMUTH OPPORTUNITY LTD.
Common Stock Purchase Agreement • May 31st, 2006 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York

This COMMON STOCK PURCHASE AGREEMENT, made and entered into on this 30th day of May 2006 (this “Agreement”), by and between Azimuth Opportunity Ltd., an international business company incorporated under the laws of the British Virgin Islands (the “Investor”), and Isis Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”).

W I T N E S S E T H :
The Stock Purchase Agreement • September 2nd, 1999 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
1 EXHIBIT 10.2
Agreement • August 12th, 1997 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
RESEARCH COLLABORATION AND LICENSE AGREEMENT
Research Collaboration and License Agreement • August 14th, 1998 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • May 24th, 2002 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York

THIS REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made and entered into as of May 1, 2002, by and between Isis Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and UBS Warburg LLC and the other Initial Purchasers named in the Purchase Agreement referred to below (collectively, the “Initial Purchasers”), for whom UBS Warburg LLC is acting as representative, pursuant to that certain Purchase Agreement, dated as of April 26, 2002 (the “Purchase Agreement”) between the Company and the Initial Purchasers.

EXHIBIT 99.1 COMMON STOCK PURCHASE AGREEMENT DATED AS OF ___________________, 1999 BY AND BETWEEN ISIS PHARMACEUTICALS, INC.
Common Stock Purchase Agreement • March 31st, 1999 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
IONIS PHARMACEUTICALS, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of April 12, 2021 0% Convertible Senior Notes due 2026
Ionis Pharmaceuticals Inc • April 13th, 2021 • Pharmaceutical preparations • New York

INDENTURE dated as of April 12, 2021 between IONIS PHARMACEUTICALS, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and U.S. BANK NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee,” as more fully set forth in Section 1.01).

CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. Sections 200.80(b)4, AND 240.24b-2 COLLABORATION AGREEMENT
Collaboration Agreement • January 4th, 2002 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • California
Time is Money Join Law Insider Premium to draft better contracts faster.